EGFR and neoplasm: The benefit of first-line chemotherapy plus cetuximab or panitumumab in L-sided mCRC has been clearly demonstrated (5), while clinical evidence on the role of primary tumor site in predicting benefit from EGFR inhibitors in pretreated mCRC patients is still limited.